Provided by Tiger Fintech (Singapore) Pte. Ltd.

CytoMed Therapeutics Limited

2.48
-0.1900-7.12%
Post-market: 2.520.0400+1.61%16:00 EDT
Volume:4.62K
Turnover:11.66K
Market Cap:28.62M
PE:-12.67
High:2.58
Open:2.55
Low:2.46
Close:2.67
Loading ...

Company Profile

Company Name:
CytoMed Therapeutics Limited
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
- -
Office Location:
1 Commonwealth Lane, No. 08-22,Singapore,Singapore
Zip Code:
149544
Fax:
- -
Introduction:
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Directors

Name
Position
CHOO Chee Kong
Chairman and Director
Lucas LUK Tien Wee
Chief Clinical Officer and Director

Shareholders

Name
Position
TAN Wee Kiat
Chief Operating Officer
GOH Yvonne
Chief Financial Officer
CHOO Chee Kong
Chairman and Director
Lucas LUK Tien Wee
Chief Clinical Officer and Director
TAN Yoong Ying
Chief Corporate Officer
ZENG Jieming
Chief Scientific and Medical Officer